Novo Nordisk A/S logo

NOVO B - Novo Nordisk A/S Share Price

DKK415.75 2.9  0.7%

Last Trade - 2:56pm

Sector
Healthcare
Size
Large Cap
Market Cap £110.02bn
Enterprise Value £108.38bn
Revenue £13.57bn
Position in Universe 2nd / 1652
Bullish
Bearish
Unlock NOVO B Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NOVO B Revenue Unlock NOVO B Revenue

Net Income

NOVO B Net Income Unlock NOVO B Revenue

Normalised EPS

NOVO B Normalised EPS Unlock NOVO B Revenue

PE Ratio Range

NOVO B PE Ratio Range Unlock NOVO B Revenue

Dividend Yield Range

NOVO B Dividend Yield Range Unlock NOVO B Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
NOVO B EPS Forecasts Unlock NOVO B Revenue
Profile Summary

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated November 28, 1931
Public Since May 17, 1974
No. of Shareholders: n/a
No. of Employees: 42,158
Sector Healthcare
Industry Pharmaceuticals
Index FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 300 , FTSEurofirst 300 Ex Eurozone, FTSEurofirst 300 Ex UK, FTSE Global 100,
Exchange OMX Nordic Exchange - Copenhagen
Shares in Issue 2,343,564,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NOVO B Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NOVO B
Upcoming Events for NOVO B
Wednesday 5th February, 2020
Q4 2019 Novo Nordisk A/S Earnings Release
Friday 20th March, 2020 Estimate
Novo Nordisk A/S Annual Shareholders Meeting
Thursday 26th March, 2020
Novo Nordisk A/S Annual Shareholders Meeting
Friday 1st May, 2020 Estimate
Q1 2020 Novo Nordisk A/S Earnings Release
Similar to NOVO B
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.